Sign in
4

Changes in Ownership

SAB Biotherapeutics, Inc. Filed Acc 0001012975-25-000592

Director acquired 1,740,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Sessa Capital (Master), L.P. · Director

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-09-29 Exercise or conversion : show line 1 in the form +1,740,000 $1.75 $3,045,000 2,198,457 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-09-29 Exercise or conversion : show line 2 in the form Series B Convertible Preferred Stock −17,400 211,100 D
Loading xslF345X05/form4.xml…